The effect of zidovudine on chronic myelopathy associated with HTLV-1
✍ Scribed by O. Gout; A. Gessain; Mt. Iba-Zizen; S. Kouzan; F. Bolgert; G. Thé; O. Lyon-Caen
- Publisher
- Springer
- Year
- 1991
- Tongue
- English
- Weight
- 203 KB
- Volume
- 238
- Category
- Article
- ISSN
- 0340-5354
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The oncoprotein Tax was characterized genetically from a large cohort of human T‐cell lymphotropic virus type 1 (HTLV‐1) seropositive individuals from the most endemic region of HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) and HTLV‐1 infection in Argentina, the pr
The nucleotide sequence of human T-lymphotropic virus type I (HTLV-I) in central nervous system tissue was determined in 3 autopsy cases with HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) and 1 seropositive carrier without HAM/TSP but with multiple sclerosis. All HAM/TSP samp
## Abstract The human T‐cell lymphotropic virus type 1 (HTLV‐1) is the etiological agent of HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), a progressive disease causing paraparesis of the lower limbs. Only a minority of persons infected with HTLV‐1 develop HAM/TSP. Universal s